Understanding and Anticipating Therapeutic and ADverse Responses in Anti-cancer Immune Checkpoint Inhibition Towards a Better Therapeutic Management of Patients
RecruitingOBSERVATIONAL
Enrollment
200
Participants
Timeline
Start Date
February 9, 2024
Primary Completion Date
February 9, 2029
Study Completion Date
February 9, 2029
Conditions
Cancer
Trial Locations (1)
29200
RECRUITING
Brest University Hospital, Brest
All Listed Sponsors
lead
University Hospital, Brest
OTHER
NCT05973344 - Understanding and Anticipating Therapeutic and ADverse Responses in Anti-cancer Immune Checkpoint Inhibition Towards a Better Therapeutic Management of Patients | Biotech Hunter | Biotech Hunter